Compare WIA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WIA | CHRS |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.8M | 186.0M |
| IPO Year | N/A | 2014 |
| Metric | WIA | CHRS |
|---|---|---|
| Price | $8.25 | $1.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.51 |
| AVG Volume (30 Days) | 39.2K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 12.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.34 |
| Revenue | N/A | ★ $277,728,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $67.29 |
| P/E Ratio | ★ N/A | $1.01 |
| Revenue Growth | N/A | ★ 152.07 |
| 52 Week Low | $7.56 | $0.71 |
| 52 Week High | $8.91 | $1.89 |
| Indicator | WIA | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 53.44 |
| Support Level | $8.19 | $1.18 |
| Resistance Level | $8.29 | $1.45 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 29.17 | 77.34 |
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.